Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
DNLI | US
-0.40
-1.38%
Healthcare
Biotechnology
30/06/2024
04/10/2024
28.63
28.51
28.97
28.38
Denali Therapeutics Inc. a biopharmaceutical company discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate including BIIB122/DNL151 a small molecule inhibitor which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593 which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919 which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343 which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788 which is in phase II clinical trial for the treatment of ALS multiple sclerosis (MS) and Alzheimer's disease; and SAR443122/DNL758 which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company Genentech Inc. Sanofi F-star Gamma Limited F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H F-star Biotechnology Limited Genzyme Corporation and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Price Below SMA10D
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
26.9%1 month
43.5%3 months
48.9%6 months
52.9%-
-
3.04
0.04
0.03
-8.66
2.66K
-
-494.61M
4.10B
4.10B
-
-39.09K
-
-100.00
-32.61
10.28
7.69
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.26
Range1M
7.66
Range3M
12.39
Rel. volume
0.36
Price X volume
10.32M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Biohaven Pharmaceutical Holding Company Ltd | BHVN | Biotechnology | 47.63 | 4.50B | -0.75% | n/a | 7.75% |
Crinetics Pharmaceuticals Inc | CRNX | Biotechnology | 53.14 | 4.25B | -1.63% | n/a | 6.42% |
Arcellx Inc. Common Stock | ACLX | Biotechnology | 78.23 | 4.21B | 2.62% | n/a | 15.25% |
Axsome Therapeutics Inc | AXSM | Biotechnology | 86.59 | 4.16B | -7.13% | n/a | 186.48% |
CRISPR Therapeutics AG | CRSP | Biotechnology | 45.37 | 3.86B | -0.74% | n/a | 11.68% |
Merus N.V | MRUS | Biotechnology | 51.78 | 3.53B | 2.41% | n/a | 1.48% |
MoonLake Immunotherapeutics | MLTX | Biotechnology | 55.28 | 3.48B | 6.68% | n/a | 0.64% |
TG Therapeutics Inc | TGTX | Biotechnology | 22.23 | 3.44B | -0.67% | 35.04 | 63.38% |
Apellis Pharmaceuticals Inc | APLS | Biotechnology | 27.51 | 3.35B | -3.41% | n/a | 179.52% |
Dynegy Inc | DYN | Biotechnology | 32.58 | 3.27B | -8.35% | n/a | 3.32% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
BRP Inc | DOOO | Recreational Vehicles | 59.31 | 4.30B | 2.21% | 24.84 | 552.13% |
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -8.66 | 0.76 | Cheaper |
Ent. to Revenue | 2,656.72 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 3.04 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 48.89 | 74.67 | Lower Risk |
Debt to Equity | 0.04 | -1.82 | Expensive |
Debt to Assets | 0.03 | 0.26 | Cheaper |
Market Cap | 4.10B | 3.73B | Par |